A detailed history of Jpmorgan Chase & CO transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 11,721 shares of GALT stock, worth $29,185. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,721
Previous 1,871 526.46%
Holding current value
$29,185
Previous $4,000 550.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$2.13 - $4.2 $20,980 - $41,370
9,850 Added 526.46%
11,721 $26,000
Q1 2024

May 10, 2024

BUY
$1.6 - $2.44 $76 - $117
48 Added 2.63%
1,871 $4,000
Q4 2023

Feb 12, 2024

BUY
$1.6 - $2.18 $2,768 - $3,771
1,730 Added 1860.22%
1,823 $3,000
Q3 2023

Nov 14, 2023

BUY
$1.38 - $1.97 $69 - $98
50 Added 116.28%
93 $0
Q3 2021

Nov 12, 2021

BUY
$2.59 - $4.15 $111 - $178
43 New
43 $0

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $148M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.